By Michael King
In August, we expected a strong finish to the year for the biotech sector. Obviously, the Sept. 11 attacks have significantly altered investors’ attitudes about the market and economy. Most recently, many have remained wary as fears of a silent, stealthier weapon, against which we have little defense, have spread across the country.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
